Kushner, Tatyana
Fairchild, Angelyn
Johnson, F. Reed
Sands, Bruce E.
Mahadevan, Uma
Subramanian, Sreedhar
Ananthakrishnan, Ashwin
Ha, Christina
Bewtra, Meenakshi http://orcid.org/0000-0002-6489-7043
Funding for this research was provided by:
American College of Gastroenterology (Pilot Research Award)
Article History
Accepted: 18 October 2021
First Online: 9 November 2021
Declarations
:
: Dr. Kushner received an American College of Gastroenterology Pilot Research Award to support this project.
: TK has participated in an advisory board for Gilead. BS has received consulting fees from 4D Pharma, AbbVie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, enGene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lilly, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, and Vivelix Pharmaceuticals; honoraria for speaking in continuing medical education (CME) programs from Takeda, Janssen, Lilly, Gilead, Pfizer, and Genentech; and research funding from Celgene, Pfizer, Takeda, Theravance Biopharma R&D, and Janssen. UM has received consulting fees from Janssen, AbbVie, Takeda, Gilead, and Bristol Myers Squibb and research funding from Pfizer, Celgene, and Genentech. SS has received speaker fees from Merck Sharpe & Dohme, AbbVie, Dr. Falk Pharmaceuticals, Takeda, and Janssen and educational grants from Takeda and Janssen. AA has received consulting fees from Kyn Therapeutics and Sun Pharma. CH has received advisory/consultant fees from AbbVie, Galen Atlantica, Genentech, Janssen, Pfizer, Salix, and Takeda; grant support from Pfizer; and honoraria for speaking from AbbVie, Medical Education Network, Prova Education, Vindico, and Imedex. MB has received research funding from Janssen, GlaxoSmithKline, and Takeda; has served as a consultant for Janssen, AbbVie, Bristol Myers Squibb, and Pfizer; and has received honorarium for participation in a CME program sponsored by AbbVie. AF has received salary or subcontractor research support fees supported in part by research funding from AbbVie, Janssen, Pfizer, Grifols, GlaxoSmithKline, Genentech, Lilly, and Amgen. FRJ has made available online a detailed listing of financial disclosures: ExternalRef removed.
: The <b>s</b>urvey is provided in the ESM. Data are available upon request.
: The study and final survey instrument were approved by all participating institutions. Ethics approval was obtained at each institution under each institutional review board under expedited procedure.
: AF assisted with the conduct of the study and designing the statistical analysis, performed data analysis, interpreted the data, and edited the manuscript. TK assisted with the research protocol and the conduct of the study, interpreted the data, and edited the manuscript. FRJ assisted with the research protocol, the conduct of the study, and designing the statistical analysis; performed data analysis; interpreted the data; and edited the manuscript. BS assisted with the research protocol, planning the study, and interpretation of data, and edited the manuscript. UM assisted with planning the study and edited the manuscript. SS assisted with the study design, the research protocol, interpretation of data, and manuscript editing. AA assisted with data collection and edited the manuscript. CH assisted with data collection and edited the manuscript. MB assisted with writing the research protocol and the planning and conduct of the study, assisted in data analysis, interpreted the data, and drafted the manuscript. She is the guarantor and affirms that the manuscript is an honest, accurate, and transparent account of the study being reported.
: All potential participants were mailed a letter with an invitation to the online survey and a unique code. Given the mailed nature of the study, written or verbal consent was not obtained. Consent was implied with completion of the study; and it was emphasized in the invitation letter that a) participation was voluntary; b) participation was confidential; c) they could quit the study at any time without penalty; d) decisions not to participate would not affect their status as a patient at the participating institution; and e) all results would be presented in aggregate and no individual identifiers would be used.
: Not applicable.
: Data is available upon request.